Patents by Inventor Youe-Kong Shue
Youe-Kong Shue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11583577Abstract: The disclosure provides a method of immunotherapy for a cancer patient, comprises administering vaccines against Globo series antigens (i.e., Globo H, Stage-specific embryonic antigen 3 “SSEA3” and Stage-specific embryonic antigen 4 “SSEA4”). Specifically, the method comprises administering Globo H-KLH (OBI-822) in patients with Metastatic Breast Cancer. The disclosure also provides a method of comprises selecting a cancer patient who is suitable as treatment candidate for immunotherapy. In addition, the disclosure provides therapeutic agents, including monoclonal antibodies (mAbs) that bind specifically to Globo series antigens and related biomarkers useful in focusing such therapeutic and diagnostic regimens.Type: GrantFiled: April 24, 2017Date of Patent: February 21, 2023Assignee: OBI PHARMA, INC.Inventors: Cheng-Der Tony Yu, Youe-Kong Shue, Chen-Hsin Liang, Peiwen Yu, Chwen-Cheng Chen
-
Publication number: 20190062342Abstract: This invention relates to novel macrolides, to the preparation of novel macrolides, to the use of such novel macrolides preventing, treating, or ameliorating various conditions, and to the use of such novel macrolides as antibacterial agents.Type: ApplicationFiled: March 23, 2018Publication date: February 28, 2019Inventors: Chang-Hsing Liang, Jonathan Duffield, Alex Romero, Yu-Hung Chiu, Steve Sucheck, Kenneth Marby, Youe-Kong Shue, Yoshitaka Ichikawa, Chan-Kou Hwang, David Rabuka, Sulan Yao
-
Publication number: 20170304419Abstract: The disclosure provides a method of immunotherapy for a cancer patient, comprises administering vaccines against Globo series antigens (i.e., Globo H, Stage-specific embryonic antigen 3 “SSEA3” and Stage-specific embryonic antigen 4 “SSEA4”). Specifically, the method comprises administering Globo H-KLH (OBI-822) in patients with Metastatic Breast Cancer. The disclosure also provides a method of comprises selecting a cancer patient who is suitable as treatment candidate for immunotherapy. In addition, the disclosure provides therapeutic agents, including monoclonal antibodies (mAbs) that bind specifically to Globo series antigens and related biomarkers useful in focusing such therapeutic and diagnostic regimens.Type: ApplicationFiled: April 24, 2017Publication date: October 26, 2017Inventors: Cheng-Der Tony YU, Youe-Kong SHUE, Chen-Hsin LIANG, Peiwen YU, Chwen-Cheng CHEN
-
Publication number: 20160280718Abstract: This invention relates to novel macrolides, to the preparation of novel macrolides, to the use of such novel macrolides preventing, treating, or ameliorating various conditions, and to the use of such novel macrolides as antibacterial agents.Type: ApplicationFiled: November 4, 2015Publication date: September 29, 2016Inventors: Chang-Hsing Liang, Jonathan Duffield, Alex Romero, Yu-Hung Chiu, Steve Sucheck, Kenneth Marby, Youe-Kong Shue, Yoshitaka Ichikawa, Chan-Kou Hwang, David Rabuka, Sulan Yao
-
Patent number: 9200026Abstract: Described herein are novel macrolides, the preparation of novel macrolides, the use of novel macrolides for preventing, treating, or ameliorating various conditions, and the use of novel macrolides as antibacterial agents.Type: GrantFiled: December 20, 2012Date of Patent: December 1, 2015Assignee: MERCK SHARP & DOHME CORP.Inventors: Chang-Hsing Liang, Jonathan Duffield, Alex Romero, Yu-Hung Chiu, Steve Sucheck, Kenneth Marby, Youe-Kong Shue, Yoshitaka Ichikawa, Chan-Kou Hwang, David Rabuka, Sulan Yao
-
Patent number: 8916527Abstract: The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically GI infections caused by toxin producing strains of Clostridium difficile (C. difficile) and Clostridium perfringens (C. perfringens).Type: GrantFiled: March 15, 2013Date of Patent: December 23, 2014Assignee: Optimer Pharmaceuticals, Inc.Inventors: Yoshi Ichikawa, Yu-Hung Chiu, Youe-Kong Shue, Farah Kondori Babakhani
-
Patent number: 8883986Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.Type: GrantFiled: March 4, 2009Date of Patent: November 11, 2014Assignee: Optimer Pharmaceuticals, Inc.Inventors: Yu-Hung Chiu, Tessie Mary Che, Alex Romero, Yoshi Ichikawa, Youe-Kong Shue
-
Publication number: 20140315838Abstract: The present invention relates to methods of treating a recurring gastrointestinal (GI) infection of Clostridium difficile in a subject comprising administering to the subject an effective amount of the compounds of the present invention.Type: ApplicationFiled: June 28, 2013Publication date: October 23, 2014Applicant: Optimer Pharmaceuticals, Inc.Inventors: Youe-Kong Shue, Sherwood Gorbach, Pamela Sears
-
Patent number: 8859510Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.Type: GrantFiled: January 22, 2008Date of Patent: October 14, 2014Assignee: Optimer Pharmaceuticals, Inc.Inventors: Yu-Hung Chiu, Tessie Mary Che, Alex Romero, Yoshi Ichikawa, Youe-Kong Shue
-
Publication number: 20140296498Abstract: Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.Type: ApplicationFiled: May 19, 2014Publication date: October 2, 2014Applicant: Optimer Pharmaceuticals, Inc.Inventors: Youe-Kong Shue, Chi-Jen Frank Du, Ming-His Chiou, Mei-Chiao Wu, Yuan-Ting Chen, Franklin W. Okumu, Jonathan James Duffield
-
Patent number: 8728796Abstract: Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.Type: GrantFiled: June 12, 2012Date of Patent: May 20, 2014Assignee: Optimer Pharmaceuticals, Inc.Inventors: Youe-Kong Shue, Chi-Jen Frank Du, Ming-His Chiou, Mei-Chiao Wu, Yuan-Ting Chen, Franklin W. Okumu, Jonathan James Duffield
-
Publication number: 20130331347Abstract: The present invention relates to methods of treating Clostridium difficile infection in a subject receiving antibiotic therapy for a different infection comprising administering to the subject an effective amount of the compounds described herein.Type: ApplicationFiled: June 28, 2013Publication date: December 12, 2013Applicant: Optimer Pharmaceuticals, Inc.Inventors: Youe-Kong Shue, Sherwood Gorbach, Pamela Sears
-
Patent number: 8586551Abstract: The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.Type: GrantFiled: August 31, 2009Date of Patent: November 19, 2013Assignee: Optimer Pharmaceuticals, Inc.Inventors: Youe-Kong Shue, Chan-Kou Hwang, Yu-Hung Chiu, Alex Romero, Farah Babakhani, Pamela Sears, Franklin Okumu
-
Publication number: 20130274175Abstract: This invention relates to the treatment or prevention of diseases associated with the use of antibiotics or cancer chemotherapies or antiviral therapies, such as colitis, pseudomembranous colitis, antibiotic associated diarrhea and infections due to C. difficile, C. perfringens, Staphylococcus species including methicillin-resistant Staphylococcus aureus (MRSA) or Enterococcus including vancomycin-resistant enterococci (VRE) with Compound I.Type: ApplicationFiled: April 26, 2012Publication date: October 17, 2013Applicant: OPTIMER PHARMACEUTICALS, INC.Inventors: Youe-Kong Shue, Farah Kondori Babakhani, Franklin W. Okumu, Pamela Suzanne Sears, Starr Louise Miller-Shangle, Robert Brian Walsh
-
Publication number: 20130252914Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicant: Optimer Pharmaceuticals, Inc.Inventors: Yu-Hung Chiu, Tessie Mary Che, Alex Romero, Yoshi Ichikawa, Youe-Kong Shue
-
Publication number: 20130252913Abstract: The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicant: Optimer Pharmaceuticals, Inc.Inventors: Youe-Kong Shue, Chan-Kou Hwang, Yu-Hung Chiu, Alex Romero, Farah Babakhani, Pamela Sears, Franklin Okumu
-
Publication number: 20130252912Abstract: The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically GI infections caused by toxin producing strains of Clostridium difficile (C. difficile) and Clostridium perfringens (C. perfringens).Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicant: Optimer Pharmaceuticals, Inc.Inventors: Yoshi Ichikawa, Yu-Hung Chiu, Youe-Kong Shue, Farah Kondori Babakhani
-
Patent number: 8518899Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.Type: GrantFiled: September 2, 2009Date of Patent: August 27, 2013Assignee: Optimer Pharmaceuticals, Inc.Inventors: Yu-Hung Chiu, Tessie Mary Che, Alex Romero, Yoshi Ichikawa, Youe-Kong Shue
-
Patent number: 8445654Abstract: The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically GI infections caused by toxin producing strains of Clostridium difficile (C. difficile) and Clostridium perfringens (C. perfringens).Type: GrantFiled: October 24, 2011Date of Patent: May 21, 2013Assignee: Optimer Pharmaceuticals, Inc.Inventors: Yoshi Ichikawa, Yu-Hung Chiu, Youe-Kong Shue, Farah Kondori Babakhani
-
Publication number: 20130123477Abstract: Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.Type: ApplicationFiled: June 12, 2012Publication date: May 16, 2013Applicant: OPTIMER PHARMACEUTICALS, INC.Inventors: Youe-Kong Shue, Chi-Jen Frank Du, Ming-His Chiou, Mei-Chiao Wu, Yuan-Ting Chen, Franklin W. Okumu, Jonathan James Duffield